{"id":16540,"date":"2022-03-10T16:16:07","date_gmt":"2022-03-10T10:46:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16540"},"modified":"2022-03-10T16:16:10","modified_gmt":"2022-03-10T10:46:10","slug":"medtech-news-for-bioventus-surgentec-exactech-boston-scientific","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific","title":{"rendered":"Bioventus\u2019s StimRouter Pain Management Device; FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; Exactech\u2019s Humeral Reconstruction Prosthesis; Boston Scientific\u2019s WATCHMAN FLX LAAC Device; PathMaker Neuro\u2019s MyoRegulator"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d5eee8ce8b9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d5eee8ce8b9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\/#Bioventus_Receives_501k_Clearance_for_StimRouter_Pain_Management_Device\" >Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\/#Valencia_Technologies_Announces_FDA_Approval_of_eCoin%C2%AE_Therapy_to_Treat_Urinary_Urge_Incontinence\" >Valencia Technologies Announces FDA Approval of eCoin\u00ae Therapy to Treat Urinary Urge Incontinence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\/#SurGenTec_Launches_ION_Screw_Smallest_Posterior_Spinal_Fixation_Implant_to_Market_After_Receiving_FDA_Clearance\" >SurGenTec Launches ION Screw, Smallest Posterior Spinal Fixation Implant, to Market After Receiving FDA Clearance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\/#Exactech_Announces_Launch_of_Humeral_Reconstruction_Prosthesis_in_Europe\" >Exactech Announces Launch of Humeral Reconstruction Prosthesis in Europe<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\/#PathMaker_Neuro_systems_Initiate_US_Multi-Center_Trial_Evaluating_MyoRegulator%C2%AE_for_the_Non-Invasive_Treatment_of_Post-Stroke_Spasticity\" >PathMaker Neuro systems Initiate U.S. Multi-Center Trial Evaluating MyoRegulator\u00ae for the Non-Invasive Treatment of Post-Stroke Spasticity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\/#Late-Breaking_Study_Results_Reinforce_Positive_Real-World_Outcomes_with_the_WATCHMAN_FLX%E2%84%A2_LAAC_Device\" >Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX&#x2122; LAAC Device<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-bioventus-receives-501-k-clearance-for-stimrouter-pain-management-device\"><span class=\"ez-toc-section\" id=\"Bioventus_Receives_501k_Clearance_for_StimRouter_Pain_Management_Device\"><\/span><strong>Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>March 1, 2022, <\/strong>the US Food and Drug Administration (FDA) gave Bioventus&#8217; StimRouter Neuromodulation System 510(k) approval. The next-generation pain treatment device is intended to treat chronic pain caused by peripheral nerves,&nbsp;excluding&nbsp;craniofacial pain. StimRouter is a minimally invasive device that includes an implanted thin lead with a conductive electrode, the StimRouter Plus Mobile Application, and an external electric field conductor (E-EFC).<\/p>\n\n\n\n<p>Bioventus chief commercial officer John Nosenzo commented, <em>\u201cThe impact of chronic, debilitating pain is more than just managing the impacted anatomy, it is also about helping return the individual back to a life pre-pain.<\/em> <em>The emotional and psychological damage from living with pain is horrific and we are pleased to support all the physicians who are committed to improving patient lives, in particular with alternatives to opioids when possible. The next generation StimRouter will support patients and physicians to meet their pain treatment goals as the previous generation of peripheral nerve stimulation has done for many years.\u201d<\/em><\/p>\n\n\n\n<p>It transmits&nbsp;electrical impulses from the E-EFC through the skin and routes them to the targeted nerve through the implanted lead. The latest version of the StimRouter technology provides similar scientifically proven, long-term pain relief while also vastly improving patient control and user comfort.<\/p>\n\n\n\n<p>According to<strong> DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuromodulation-devices-market\"><strong>Neuromodulation Devices Market<\/strong><\/a><strong>\u201d <\/strong>report<strong>, <\/strong>the global Neuromodulation Devices market was valued at <strong>USD 5.25 billion<\/strong> in 2020, growing at a <strong>CAGR of 8.95%<\/strong> during the forecast period from 2021 to 2026, to reach <strong>USD 9.23 billion. <\/strong>The demand for neuromodulation devices is primarily motivated by the <a href=\"https:\/\/www.delveinsight.com\/blog\/key-companies-in-neurological-disorders-market\">increasing prevalence of neurological disorders<\/a> coupled with the rising aging population, expansion of the devices to other chronic indications and target application, technological advancement in the product portfolio, the rising government initiative to raise awareness among patient regarding neurological disorders, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Valencia_Technologies_Announces_FDA_Approval_of_eCoin%C2%AE_Therapy_to_Treat_Urinary_Urge_Incontinence\"><\/span><strong>Valencia Technologies Announces FDA Approval of eCoin\u00ae Therapy to Treat Urinary Urge Incontinence<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>March 1, 2022, <\/strong>Valencia Technologies Corporation, a privately held company, announced the US Food and Drug Administration (FDA) gave its eCoin\u00ae leadless tibial neurostimulator premarket approval (PMA) for the treatment of urinary urge incontinence (UUI), which affected over 60% of patients with Overactive Bladder (OAB). The effectiveness and favorable safety profile revealed in the eCoin\u00ae pivotal study aided the FDA to approve.<\/p>\n\n\n\n<p>eCoin\u00ae is a nickel-sized neurostimulator that is implanted subcutaneously in the lower leg using a local anesthetic during a minimally invasive outpatient procedure. eCoin\u00ae is the first FDA-approved implantable tibial nerve stimulator. The eCoin\u00ae equipment has the main battery and, once set, gives intermittent stimulation to the tibial nerve to help with UUI symptoms.<\/p>\n\n\n\n<p>Jeff Greiner, Founder of Valencia, said, <em>\u201cThis is a landmark approval for physicians and UUI patients as eCoin\u00ae is now the first and only implantable tibial nerve stimulator approved by the FDA. eCoin\u00ae will facilitate a paradigm shift for UUI treatments by offering physicians an efficient option for implantation with high patient satisfaction. The simplicity and effectiveness of eCoin\u00ae will enable more patients to achieve the help they desperately need.\u201d<\/em><\/p>\n\n\n\n<p>The eCoin\u00ae implantable device is leadless, which means there are no delicate wires that must be properly tunneled to reach the desired nerve for therapy. Instead, the eCoin\u00ae device is implanted just above the ankle over the tibial nerve, and its forgiving, dome-shaped stimulation field stimulates the nerve regularly to relax the bladder and alleviate bladder leakage.<\/p>\n\n\n\n<p>Dr. Rebecca McCrery, an Investigator in the eCoin\u00ae pivotal trial, said, <em>\u201cBeyond delivering impressive results achieved without the need for prior screening, the eCoin\u00ae procedure is easily understood by patients, reproducible amongst physicians, and accomplished in a safe and effective manner. Under 5% of OAB patients select burdensome third-line interventions due to invasiveness or potential side effects of available therapies and limitations in access, resulting in a staggering unmet clinical need. The effortless relief provided by the automatic nature of eCoin\u00ae neuromodulation therapy will potentially better treat the vast population \u2013 often desperate for relief \u2013 who are not well managed by the current options available to them.\u201d<\/em><\/p>\n\n\n\n<p>The pivotal study, which tracked 133 women and men in the United States who were implanted with eCoin\u00ae, was used to support the PMA application for eCoin\u00ae. In the per-protocol group, 75% of patients experienced a 50% reduction in UUI occurrences. Before implantation, there was no trial or screening. One year after the treatment, 81% of patients said they felt &#8220;better&#8221; to &#8220;very much better.&#8221; Implanted patients had a positive experience, with 97% claiming the surgery was appropriately described to them and 89% reporting they would suggest eCoin\u00ae treatment to friends or family.&nbsp; The company planned to commercialize eCoin\u00ae in March 2022, with medical training starting in April 2022.<\/p>\n\n\n\n<p>According to<strong> DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/urinary-incontinence-devices-market\"><strong>Urinary Incontinence Devices Market<\/strong><\/a><strong>\u201d <\/strong>report<strong>, <\/strong>the global Urinary Incontinence Devices market was valued at USD 2.8 billion in 2020, growing at a CAGR of 6.32% during the forecast period from 2021 to 2026, to reach USD 4.03 billion by 2026. The Urinary Incontinence Devices market is expected to witness growth due to the rising prevalence of urinary incontinence cases, development of innovative devices, aging population prone to urological conditions like urinary tract infections, weakening of pelvic floor, and conditions including pregnancy, diabetes, menopause, and Parkinson\u2019s disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SurGenTec_Launches_ION_Screw_Smallest_Posterior_Spinal_Fixation_Implant_to_Market_After_Receiving_FDA_Clearance\"><\/span><strong>SurGenTec Launches ION Screw, Smallest Posterior Spinal Fixation Implant, to Market After Receiving FDA Clearance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> March 2, 2022, <\/strong>SurGenTec\u00ae, a privately held spine and orthopedic technology firm located in Boca Raton, FL, announced its innovative stand-alone spine fixation implant, the ION<sup>TM<\/sup> Screw, has been cleared by the FDA. This one-of-a-kind device may be used to treat a range of spinal diseases from C2 to S1. The ION implant, which is smaller than a dime and can be implanted through a little incision with minimal tissue damage, is the smallest posterior fixation device certified for spine surgery. The Nanotex<sup>TM<\/sup> surface technology of ION screws has been built with bone interdigitation in mind.<\/p>\n\n\n\n<p>Travis Greenhalgh, Founder and Chief Executive Officer of SurGenTec, commented, <em>\u201cThe ION screw technology truly changes the game for spine surgery. Patients are looking for options outside traditional bulky metallic devices such as pedicle screws and interspinous plates. This minimally invasive option provides excellent fixation with zero profile. It\u2019s a non-intimidating solution for patients that need to undergo a spine surgery procedure. We are thrilled to announce the addition of ION to our portfolio. Our team has put years into pre-clinical research and development to create this truly novel spinal fixation option. Our team managed to create a \u2018micro\u2019 implant with a unique surface technology that provides fixation without the need for cumbersome implants.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>Facet fusions, adjunct to decompressive operations, the treatment of neighboring level illness, or offering further stability with interbody fusions are just a few of the open or true minimally invasive surgery (MIS) applications where ION can be used. While delivering the ION implants to the surgical region, the ION facet screw system devices were developed to reduce tissue stress and incision size.<\/p>\n\n\n\n<p>Andrew Shoup, Chief Operating Officer of SurGenTec, stated, <em>&#8220;The ION system is a great fit for the ambulatory surgery center environment by providing a cost-effective solution for physicians looking to minimize trauma while still providing a high level of spinal care to patients. Patients are demanding access to a more efficient operating environment with less risk of illness and disease transmission.&#8221;&nbsp;<\/em><\/p>\n\n\n\n<p>The ION has a zero profile above the bone, unlike conventional spinal fixation solutions, which may reduce soft tissue contact and discomfort. Before and after insertion, the implants may be packed with bone graft to aid fusion allowing bone to bridge over the implant and prevent implant migration.<\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s<\/strong> \u2018<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-fusion-devices-market\"><strong>Spinal Fusion Devices Market<\/strong><\/a><strong>\u201d <\/strong>report<strong>, <\/strong>the global Spinal Fusion Devices market was valued at<strong> USD 6.21 billion<\/strong> in 2020, growing at a <strong>CAGR of 4.57%<\/strong> during the forecast period from 2021 to 2026 to reach <strong>USD 8.08 billion<\/strong> by 2026. The rise in demand for Spinal Fusion Devices is primarily attributed to the rising prevalence of spinal disorders such as degenerative disc disorders, spondylolisthesis, disc herniation, spinal stenosis among the growing old-age population worldwide; increase in demand for minimally invasive surgeries. In addition, technological advancement in the product line and new product launches, among others, are also expected to drive the <a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-fusion-market\">global spinal fusion market<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Exactech_Announces_Launch_of_Humeral_Reconstruction_Prosthesis_in_Europe\"><\/span><strong>Exactech Announces Launch of Humeral Reconstruction Prosthesis in Europe<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> March 7, 2022,<\/strong> Exactech, a developer and manufacturer of unique joint replacement implants, instruments, and smart technologies, announced its Equinoxe\u00ae Humeral Reconstruction Prosthesis approval for clinical use in Europe.<\/p>\n\n\n\n<p>The Humeral Reconstruction Prosthesis is intended for intraoperative flexibility and patient-specific sizing. It is the first modular device offered in the United States for substantial proximal humeral bone loss and reconstruction after tumor resections. The prosthesis provides several possibilities for achieving stability irrespective of the extent of the proximal humeral excision in both simple and difficult cases. It&#8217;s employed in arthroplasty surgeries, including primary and revision, as well as anatomic oncology procedures. The humeral reconstruction prosthesis was first launched in the United States in 2015 and has since been used to treat over 1,500 patients. It is now accessible in the following countries: Italy, France, Spain, Germany, and&nbsp;Great Britain.<\/p>\n\n\n\n<p>Pietro Ruggieri, MD, Ph.D. (Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy), a design surgeon, commented, \u201c<em>The Equinoxe Humeral Reconstruction Prosthesis is designed to treat patients with a wide range of proximal humeral bone loss. This modular prosthesis is capable of reconstructing a patient\u2019s humerus with as little as 50mm of bone loss, while also being able to address the most challenging cases, including patients who have a resection below the deltoid insertion, through the use of additional modular middle segments. I am thrilled that this remarkable device is now available for the treatment of patients in Europe.\u201d<\/em><\/p>\n\n\n\n<p>The Humeral Reconstruction Prosthesis&#8217; modularity is a crucial component, with a platform stem and numerous modular segments allowing reconstruction between 50mm \u2013 212.5mm and 60mm \u2013 222.5mm, as well as several soft tissue fixation methods. Due to its unique plasma\/hydroxyapatite (HA) coated collars meant for fixation and best fit, the device is designed to provide biomechanical benefits, including rotational stability.<\/p>\n\n\n\n<p>Chris Roche, Sr. Vice President, Extremities, stated, <em>\u201cAt Exactech we challenge our development teams to create products that solve unmet clinical needs, and our Humeral Reconstruction Prosthesis is an innovative solution that was designed to address the most difficult humeral challenges shoulder surgeons face. The Humeral Reconstruction Prosthesis was the first reverse TSA device cleared for use in the U.S. for significant resection of the proximal humerus.\u201d<\/em><\/p>\n\n\n\n<p>He further added, <em>\u201cIt incorporates many unique design features intended to mitigate complications associated with these challenging cases, including collars available in 17 different sizes to achieve rotational stability and fixation for the full range of bone sizes. It also provides numerous proximal body options to achieve joint stability while also lateralizing the deltoid. Our surgeon and engineering teams are proud to deliver this unique and innovative shoulder solution to the European market.\u201d<\/em><\/p>\n\n\n\n<p>According to<strong> DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/orthopedic-prosthesis-devices-resection-guides-market\"><strong>Orthopedic Prosthesis Devices Market<\/strong><\/a><strong>\u201d, <\/strong>the global Orthopedic Prosthesis Devices Market was valued at USD 2.11 billion in 2020, growing at a CAGR of 5.88% during the forecast period from 2021 to 2026 to reach USD 2.96 billion by 2026. Orthopedic Prosthesis Devices Market is segmented into By Product Type (Upper Extremity Orthopedic Prosthesis Devices [Shoulder, Elbow, Hand &amp; Wrist, And Fingers], Lower Extremity Orthopedic Prosthesis Devices [Foot &amp; Ankle, Knee, Hip, And&nbsp; Others]), By Technology (Active [Body-Powered And Electric-Powered] And Passive), By Customization (Prefabricated And Customized), By Age Group (Adult And Pediatric), By End User (Hospitals, Ambulatory Surgical Centers, And Others), and is expected to grow at a steady CAGR forecast till 2026 owing to the increasing cases of limb amputation due to diabetes and trauma injuries.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PathMaker_Neuro_systems_Initiate_US_Multi-Center_Trial_Evaluating_MyoRegulator%C2%AE_for_the_Non-Invasive_Treatment_of_Post-Stroke_Spasticity\"><\/span><strong>PathMaker Neuro systems Initiate U.S. Multi-Center Trial Evaluating MyoRegulator\u00ae for the Non-Invasive Treatment of Post-Stroke Spasticity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> March 7, 2022,<\/strong> PathMaker Neurosystems Inc., a near-commercial neuromodulation company developing ground-breaking non-invasive systems for the treatment of serious neurological disorders, has announced the start of a multi-center clinical trial in the United States to evaluate MyoRegulator\u00ae for the non-invasive treatment of post-stroke upper-limb spasticity. The trial is being conducted with the Spaulding Rehabilitation Hospital in Charlestown, MA, and is funded by a $4.9 million NINDS Cooperative Research to Enable and Advance Translational Enterprises for Devices (CREATE Devices) grant from the National Institute of Neurological Disorders and Stroke (NINDS).<\/p>\n\n\n\n<p>PathMaker&#8217;s innovative DoubleStim\u00ae technology offers simultaneous stimulation at spinal and peripheral locations, making MyoRegulator\u00ae a first-in-class, non-invasive neuromodulation device. It&#8217;s the first and only neuromodulation device that works without medicines or surgery to treat muscular spasticity. It has been utilized&nbsp;in two completed clinical studies in the United States and Europe and has been certified as a &#8220;breakthrough&#8221; medical device by the US FDA.<\/p>\n\n\n\n<p>This pivotal study will be a multi-center, randomized, double-blind, sham-controlled trial that will compare the effectiveness and safety of MyoRegulator\u00ae therapy for post-stroke lower-limb spasticity in active vs sham-treated participants, with a total of 76 subjects enrollment.<\/p>\n\n\n\n<p>J. Leon Morales-Quezada, M.D., Ph.D., Director of the Integrative Rehabilitation Lab and Research Associate Director, Spaulding Neuromodulation Center at Spaulding Rehabilitation Hospital, and Study Site Principal Investigator for this study said, <em>\u201cThere is a pressing need for novel therapeutic options that do not involve drugs or surgery for the treatment of spasticity. The MyoRegulator\u00ae device represents potential new hope for millions of patients living with this disorder around the world. We are thrilled to be involved in this trial with PathMaker and explore bringing this technology closer to clinical practice.\u201d<\/em><\/p>\n\n\n\n<p>According to<strong> DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuromodulation-devices-market\"><strong>Neuromodulation Devices Market<\/strong><\/a><strong>\u201d <\/strong>report<strong>, <\/strong>the global Neuromodulation Devices market was valued at <strong>USD 5.25 billion in 2020,<\/strong> growing at a <strong>CAGR of 8.95%<\/strong> during the forecast period from 2021 to 2026, to reach <strong>USD 9.23 billion<\/strong>. The demand for neuromodulation devices is primarily motivated by the <a href=\"https:\/\/www.delveinsight.com\/blog\/the-growing-burden-of-neurodegenerative-disorders\">increasing prevalence of neurological disorders<\/a> coupled with the rising aging population, expansion of the devices to other chronic indications and target application, technological advancement in the product portfolio, an increasing government initiative to raise awareness among patient regarding <a href=\"https:\/\/www.delveinsight.com\/blog\/transcranial-stimulation-devices-market\">neurological disorders<\/a>, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Late-Breaking_Study_Results_Reinforce_Positive_Real-World_Outcomes_with_the_WATCHMAN_FLX%E2%84%A2_LAAC_Device\"><\/span><strong>Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX&#x2122; LAAC Device<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> February 28, 2022, <\/strong>the WATCHMAN FLX<sup>TM<\/sup> Left Atrial Appendage Closure (LAAC) Device had positive outcomes in a recent analysis conducted by Boston Scientific Corporation. The SURPASS analysis, which was presented at a late-breaking trial session at the Cardiovascular Research Technologies (CRT) 2022 meeting, included data from over 16,000 patients with non-valvular atrial fibrillation who were part of the NCDR&#8217;s Left Atrial Appendage Occlusion (LAAO) Registry.<\/p>\n\n\n\n<p>The positive outcomes showed a low rate of major adverse events of 0.37% at seven days after a WATCHMAN FLX implant or at the time of hospital discharge, whichever occurred later. A composite of all-cause mortality, ischemic stroke, systemic embolism, or device\/procedure-related events requiring open-heart surgery or substantial endovascular intervention was used to define this crucial safety endpoint. A 0.51% rate of pericardial effusion needing surgical or percutaneous intervention was found at the 45-day follow-up following a WATCHMAN FLX implant, with just 0.03% of patients requiring cardiac surgery.<\/p>\n\n\n\n<p>Dr. Samir Kapadia, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular &amp; Thoracic Institute, Cleveland Clinic, said,<em> \u201cThis analysis includes the largest number of real-world WATCHMAN FLX patients to date and provides evidence that this stroke reduction therapy is associated with a low incidence of adverse events and peri-device leak through 45 days. SURPASS represents the experience of more than 2,000 physicians using this therapy in routine clinical practice.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>The WATCHMAN FLX device was implanted successfully in 97.6% of patients in the study, and data showed minimal rates of ischemic stroke (0.28%) and device embolization (0.03%) in patients after 45 days. The SURPASS research is continuing and will continue to collect results for at least two years post-implant on all patients in the NCDR-LAAO Registry treated with WATCHMAN FLX between August 2020 and August 2022. The major effectiveness objective of occurrence of <a href=\"https:\/\/www.delveinsight.com\/report-store\/ischemic-stroke-market\">ischemic stroke<\/a> or systemic embolism will be examined after&nbsp;24 months.<\/p>\n\n\n\n<p>Dr. Ian Meredith, global chief medical officer, Boston Scientific, said,<em> \u201cThe strong safety and efficacy profile of the WATCHMAN FLX device demonstrated in the SURPASS analysis reinforces many of the safety and effectiveness results seen in the pivotal PINNACLE FLX trial while representing a high-risk, real-world patient population and a wide variety of patient anatomies. We look forward to further analyses from this large, representative study of patients with NVAF treated by physicians with a broad range of implanting experience.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>The WATCHMAN technology has been implanted in over 200,000 people worldwide, and clinical research on the use of the WATCHMAN FLX device in patients with NVAF is still underway through two large prospective, randomized controlled trials: the OPTION and CHAMPION-AF clinical trials.According to <strong>DelveInsight\u2019s \u201c\u2018<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/left-atrial-appendage-closure-devices-market\"><strong>Left Atrial Appendage Closure Devices Market<\/strong><\/a><strong>&#8221; <\/strong>report, the growing cases of atrial fibrillation is the major factor expected to boost the demand for left atrial appendage closure devices market growth. As per <strong>CDC 2021<\/strong>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/atrial-fibrillation-market\">atrial fibrillation<\/a> was mentioned on 183,321 death certificates and was the underlying cause of death in 26,535 of those deaths in 2019.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device On March 1, 2022, the US Food and Drug Administration (FDA) gave Bioventus&#8217; StimRouter Neuromodulation System 510(k) approval. The next-generation pain treatment device is intended to treat chronic pain caused by peripheral nerves,&nbsp;excluding&nbsp;craniofacial pain. StimRouter is a minimally invasive device that includes an implanted thin lead [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":16542,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19162,2753,17021,18799,18795,18901,19158,420,19161,19160,19159],"industry":[17226],"therapeutic_areas":[17242,17229,17230,17245],"class_list":["post-16540","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-left-atrial-appendage-closure-devices-market","tag-medical-device","tag-medical-devices-market","tag-medtech-news","tag-neurological-disorders","tag-neuromodulation-devices","tag-neuromodulation-devices-market","tag-news","tag-orthopedic-prosthesis-devices-market","tag-spinal-fusion-devices-market","tag-urinary-incontinence-devices-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-central-nervous-system","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech Updates | Bioventus, SurGenTec, Exactech, and PathMaker<\/title>\n<meta name=\"description\" content=\"FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; PathMaker Neuro\u2019s MyoRegulator; Exactech\u2019s Humeral Reconstruction Prosthesis\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech Updates | Bioventus, SurGenTec, Exactech, and PathMaker\" \/>\n<meta property=\"og:description\" content=\"FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; PathMaker Neuro\u2019s MyoRegulator; Exactech\u2019s Humeral Reconstruction Prosthesis\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-10T10:46:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-10T10:46:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/10161124\/Latest-MedTech-News-and-Updates-for-Bioventus-Valencia-Technologies-SurGenTec-Graftgun-Exactech-PathMaker-Neurosystems-Boston-Scientific.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech Updates | Bioventus, SurGenTec, Exactech, and PathMaker","description":"FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; PathMaker Neuro\u2019s MyoRegulator; Exactech\u2019s Humeral Reconstruction Prosthesis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific","og_locale":"en_US","og_type":"article","og_title":"MedTech Updates | Bioventus, SurGenTec, Exactech, and PathMaker","og_description":"FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; PathMaker Neuro\u2019s MyoRegulator; Exactech\u2019s Humeral Reconstruction Prosthesis","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-03-10T10:46:07+00:00","article_modified_time":"2022-03-10T10:46:10+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/10161124\/Latest-MedTech-News-and-Updates-for-Bioventus-Valencia-Technologies-SurGenTec-Graftgun-Exactech-PathMaker-Neurosystems-Boston-Scientific.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific","name":"MedTech Updates | Bioventus, SurGenTec, Exactech, and PathMaker","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/10161124\/Latest-MedTech-News-and-Updates-for-Bioventus-Valencia-Technologies-SurGenTec-Graftgun-Exactech-PathMaker-Neurosystems-Boston-Scientific.png","datePublished":"2022-03-10T10:46:07+00:00","dateModified":"2022-03-10T10:46:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; PathMaker Neuro\u2019s MyoRegulator; Exactech\u2019s Humeral Reconstruction Prosthesis","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-bioventus-surgentec-exactech-boston-scientific#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/10161124\/Latest-MedTech-News-and-Updates-for-Bioventus-Valencia-Technologies-SurGenTec-Graftgun-Exactech-PathMaker-Neurosystems-Boston-Scientific.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/10161124\/Latest-MedTech-News-and-Updates-for-Bioventus-Valencia-Technologies-SurGenTec-Graftgun-Exactech-PathMaker-Neurosystems-Boston-Scientific.png","width":772,"height":482,"caption":"MedTech News and Updates for Bioventus, Valencia Technologies, SurGenTec Graftgun, Exactech, PathMaker Neurosystems, Boston Scientific"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/10161124\/Latest-MedTech-News-and-Updates-for-Bioventus-Valencia-Technologies-SurGenTec-Graftgun-Exactech-PathMaker-Neurosystems-Boston-Scientific-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Left Atrial Appendage Closure Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurological Disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neuromodulation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neuromodulation Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orthopedic Prosthesis Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Fusion Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Urinary Incontinence Devices Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Left Atrial Appendage Closure Devices Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">Neurological Disorders<\/span>","<span class=\"advgb-post-tax-term\">Neuromodulation Devices<\/span>","<span class=\"advgb-post-tax-term\">Neuromodulation Devices Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Orthopedic Prosthesis Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Spinal Fusion Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Urinary Incontinence Devices Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Mar 10, 2022","modified":"Updated on Mar 10, 2022"},"absolute_dates_time":{"created":"Posted on Mar 10, 2022 4:16 pm","modified":"Updated on Mar 10, 2022 4:16 pm"},"featured_img_caption":"MedTech News and Updates for Bioventus, Valencia Technologies, SurGenTec Graftgun, Exactech, PathMaker Neurosystems, Boston Scientific","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16540"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16540\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16542"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16540"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16540"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}